CPIX
$2.83-0.05 (-1.74%)
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationa...
Recent News
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...
CPIX reports significant revenue growth and global expansion, while navigating increased expenses and financial commitments.
Cumberland Pharmaceuticals Q4 Earnings Call Highlights
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported fourth-quarter and full-year 2025 results and provided a business update during its earnings call, highlighting revenue growth across its portfolio, progress in pipeline programs led by ifetroban, and continued expansion into international markets.
Cumberland: Q4 Earnings Snapshot
CPIX) on Tuesday reported a loss of $1.4 million in its fourth quarter. On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 9 cents. Losses, adjusted for one-time gains and costs, came to 1 cent per share.
Niche Focus & Regulation Shape the Future of Healthcare Firms
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.